A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

Srdan Verstovsek, Stephane Courby, Martin Griesshammer, Ruben A. Mesa, Carrie Baker Brachmann, Jun Kawashima, Julia D. Maltzman, Lixin Shao, Yan Xin, Daniel Huang, Ashish Bajel

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Fingerprint Dive into the research topics of 'A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia'. Together they form a unique fingerprint.

Medicine & Life Sciences